Literature DB >> 18241242

Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease.

José L Albasanz1, Sandra Perez, Marta Barrachina, Isidro Ferrer, Mairena Martín.   

Abstract

Adenosine receptors are G-protein coupled receptors which modulate neurotransmitter release, mainly glutamate. Adenosine A(1) and A(2A) receptors were studied in post-mortem human cortex in Alzheimer's disease (AD) and age-matched controls. Total adenosine A(1) receptor number, determined by radioligand binding assay, using [(3)H]DPCPX, was significantly increased in AD cases in early and advanced stages without differences with the progression of the disease. A significant increase of A(1)R (37 kDa) levels was also observed by Western blot in early and advanced stages of AD. In addition, increased numbers of adenosine A(2A) receptors were observed in AD samples as determined by a binding assay using [(3)H]ZM 241385 as a radioligand and by Western blot. Increased binding and protein expression levels of adenosine receptors were not associated with increased mRNA levels coding A(1) and A(2A) receptors. Finally, increased A(1) and A(2A) receptor-mediated response was observed. These results show up-regulation of adenosine A(1) and A(2A) receptors in frontal cortex in AD, associated with sensitization of the corresponding transduction pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18241242     DOI: 10.1111/j.1750-3639.2007.00112.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  48 in total

Review 1.  DREADDS: Use and application in behavioral neuroscience.

Authors:  Kyle S Smith; David J Bucci; Bryan W Luikart; Stephen V Mahler
Journal:  Behav Neurosci       Date:  2016-02-25       Impact factor: 1.912

2.  Adenosine A(2A) receptors are necessary and sufficient to trigger memory impairment in adult mice.

Authors:  N Pagnussat; A S Almeida; D M Marques; F Nunes; G C Chenet; P H S Botton; S Mioranzza; C M Loss; R A Cunha; L O Porciúncula
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

3.  A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.

Authors:  C Laurent; S Burnouf; B Ferry; V L Batalha; J E Coelho; Y Baqi; E Malik; E Mariciniak; S Parrot; A Van der Jeugd; E Faivre; V Flaten; C Ledent; R D'Hooge; N Sergeant; M Hamdane; S Humez; C E Müller; L V Lopes; L Buée; D Blum
Journal:  Mol Psychiatry       Date:  2014-12-02       Impact factor: 15.992

Review 4.  Purinergic receptors as potential therapeutic targets in Alzheimer's disease.

Authors:  Lucas T Woods; Deepa Ajit; Jean M Camden; Laurie Erb; Gary A Weisman
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

5.  Modulation of adenosine receptors by [60]fullerene hydrosoluble derivative in SK-N-MC cells.

Authors:  Davide Giust; David León; Inmaculada Ballesteros-Yañez; Tatiana Da Ros; José Luis Albasanz; Mairena Martín
Journal:  ACS Chem Neurosci       Date:  2011-04-15       Impact factor: 4.418

Review 6.  Advances in protein misfolding, amyloidosis and its correlation with human diseases.

Authors:  Debanjan Kundu; Kumari Prerna; Rahul Chaurasia; Manoj Kumar Bharty; Vikash Kumar Dubey
Journal:  3 Biotech       Date:  2020-04-04       Impact factor: 2.406

Review 7.  Impact of Coffee and Cacao Purine Metabolites on Neuroplasticity and Neurodegenerative Disease.

Authors:  Simonetta Camandola; Natalie Plick; Mark P Mattson
Journal:  Neurochem Res       Date:  2018-02-08       Impact factor: 3.996

8.  Chronic treatment with DCPCX, an adenosine A(1) antagonist, worsens long-term memory.

Authors:  Craig Vollert; Gloria S Forkuo; Richard A Bond; Jason L Eriksen
Journal:  Neurosci Lett       Date:  2013-06-06       Impact factor: 3.046

9.  The role of adenosine in Alzheimer's disease.

Authors:  Anisur Rahman
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

10.  Striatal adenosine A2A receptor expression is controlled by S-adenosyl-L-methionine-mediated methylation.

Authors:  Izaskun Villar-Menéndez; Fabiana Nuñez; Sara Díaz-Sánchez; José Luis Albasanz; Jaume Taura; Víctor Fernández-Dueñas; Isidre Ferrer; Mairena Martín; Francisco Ciruela; Marta Barrachina
Journal:  Purinergic Signal       Date:  2014-06-19       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.